Shares of Becton Dickinson & Co. BDX slipped 1.60% to $225.85 Wednesday, on what proved to be an all-around rough trading ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

Becton Dickinson (BDX) rose 2.4% in premarket trading as reports surface of potential separation of its $30 billion life ...

In a regulatory filing, Becton Dickinson (BDX) disclosed that its director Jeffrey Henderson bought 1.5K shares of common stock on February ...

Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and ...

Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to 30% ...

Shares of Becton, Dickinson and Company (NYSE:BDX – Get Free Report) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports ...